Document is current
Any future updates will be listed below
-
Authors
Li, Haiyan
Liu, Juanfang
Wang, Xiaohong
Zhao, Weilong
Zhang, Lili
Niu, Xiaoye
Liu, Jingyao
Dong, Zhongqi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05151692 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics, Pharmacodynamics, and Safety of Nipocalimab in Healthy Chinese Volunteers: A Single-Dose, Phase I Study
https://doi.org/10.1007/s40120-025-00763-5
-
Funding
Funding for this research was provided by:
Johnson and Johnson, Shanghai, China
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 1 May 2025
First Online: 19 May 2025
Declarations
:
: Juanfang Liu, Weilong Zhao, Lili Zhang, and Zhongqi Dong are current employees of Johnson & Johnson. Haiyan Li, Xiaohong Wang, Xiaoye Niu, and Jingyao Liu have nothing to disclose.
: The study protocol and its amendment were reviewed and approved by an independent ethics committee at the study site (Peking University Third Hospital Medical Science Research Ethics Committee). The study was conducted in compliance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and with relevant law and regulatory requirements. All participants had provided written informed consent.
